创新药物市场准入政策环境研究——基于利益相关者视角  

A review on the policy environment of innovative drug market access:A stakeholder's perspective

作　　者：褚淑贞[1] 王恩楠 余紫君 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国卫生政策研究》2017年第8期29-33,共5页Chinese Journal of Health Policy

基　　金：国家社会科学基金重大项目(15ZDB167)

摘　　要：本文利用利益相关者理论、外部性理论和边际效用理论,分析创新药物市场准入过程中利益相关者的行为需求,得出以政府和药品企业为创新药物市场准入政策的核心和供给群落,患者和医疗机构为需求群落的创新药物市场准入各利益相关体相互作用机制,并构建上述利益相关者视角下的创新药物市场准入政策环境模型。结合我国创新药物市场准入的现状,为激励创新药物市场准入各利益相关主体,优化我国现有创新药物市场准入政策环境提出参考性建议。Based on the stakeholder theory,externalities theory and marginal utility theory,this paper analyzes the behavioral needs of stakeholders in the process of market access of innovative drugs. It also draws out the core of the government and the pharmaceutical enterprises in the policy of access to innovative drug market and supply to the community,the patients,and the medical institutions enter the mechanism of the interaction of the various stakeholders in the innovative drug market for the demand community and construct the above-mentioned stakeholder perspective Innovative Drug Market Access Policy Environment Model. Based on the status quo of China＇s innovative drug market access,the present study puts forward to encourage innovative drug market access to the interests of the main body,to optimize the existing innovative drug market access policy environment to make reference recommendations.

关 键 词：利益相关者 创新药物 市场准入 

分 类 号：R197[医药卫生—卫生事业管理]